



<http://researchspace.auckland.ac.nz>

### *ResearchSpace@Auckland*

#### **Copyright Statement**

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

#### **General copyright and disclaimer**

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

**Superantigens as vaccine delivery vehicles for the generation  
of cellular immune responses**

Mei San Loh

A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of  
Philosophy

Department of Molecular Medicine and Pathology  
The University of Auckland  
2006

## Abstract

The constant battle between pathogen and host has led to substantial diversity and adaptability of the host immune system. Pathogens too, have evolved unique mechanisms to evade their hosts. The production of superantigens is one of these mechanisms.

Superantigens are potent T cell mitogens that have the unique ability to bind simultaneously to major histocompatibility complex (MHC) class II molecules and T cell receptors (TCRs). The resulting uncontrolled activation of up to 20% of all T cells and the subsequent cytokine release, can lead to fever, shock and death. Superantigens are not processed intracellularly like conventional antigens but instead bind as intact proteins to MHC class II molecules expressed on the surface of professional antigen presenting cells.

On the hypothesis that the unique properties of superantigens may serve useful for vaccine delivery, several bacterial superantigens were selectively mutated at their TCR-binding site with the ultimate goal of creating a safe, non-toxic carrier protein that could target antigen presenting cells by binding to MHC class II.

Antigen presenting cells that expressed MHC class II were indeed targeted by the TCR-binding-deficient superantigens. Cellular internalisation of the superantigen into vesicles was observed as early as 30 min. These superantigens were also shown to traffic to, and be captured by, the lymph nodes of immunised mice. Using TCR-binding-deficient superantigens as vaccine carrier proteins, enhanced antigenicity and immunogenicity of the conjugated MHC class I-restricted peptide antigen, GP33, was observed in a mouse model. *In vitro* studies revealed up to 200-fold enhancement of antigenicity when GP33 was conjugated to superantigen. Enhanced immunogenicity was also observed *in vivo*, with

conjugates providing protection against Lymphocytic choriomeningitis virus infection after only a single immunisation. These results indicate that modified superantigens are able to safely deliver peptides for cross-presentation, and may serve as a novel mechanism for vaccine delivery.

In memory of Donald Loh  
Your love, support, and guidance will be with me always

## Acknowledgements

I would like to thank Professor John Fraser for giving me the incredible opportunity to work on this project. His inspirational attitude towards science will always be remembered.

Thank you to my co-supervisors Birgit Schrage and Diana Schuhbauer for their guidance, advice and friendship.

To past, present and honorary members of the Lab: Indira Basu, Fiona Clow, Matthew Chung, Vanessa Handley, Nicola Jackson, Ries Langely, Guy Moffatt, Thomas Proft, Amanda Taylor, Natasha Willoughby, Phillip Webb and Lily Yang, thank you for your contributions and for being a second family to me.

Thank you to all my friends, especially to the “dinner out girls”: Carissa Fonseca, Nimali Withana and Lily Yang, for which without their love and support would not have made this chapter in my life complete.

To Donald, Rosie and Selina, for being the best family anyone could hope for. Mum, thank you for sacrificing so much for me and for putting up with me for all these years.

To Regan Hughes, not only for the tough job of proof-reading this thesis, but also for believing in me and helping me through the tough times. Thank you for your endless encouragement and unconditional love.

This work was generously supported by scholarships and research grants from the University of Auckland, the Health Research Council of New Zealand and Auckland UniServices.

## Table of Contents

Abstract.....	II
Acknowledgements.....	V
List of figures.....	XIII
List of Tables.....	XVI
Abbreviations.....	XVII

### CHAPTER 1

#### Introduction

1.1 Bacterial Superantigens.....	1
1.1.1 Overview.....	1
1.1.2 Superantigens produced by <i>Staphylococcus aureus</i> .....	3
1.1.3 Superantigens produced by <i>Streptococcus pyogenes</i> .....	3
1.1.4 Structure of staphylococcal and streptococcal superantigens.....	4
1.1.5 Superantigen interaction with MHC class II.....	9
a) Alpha-chain-binding superantigens.....	11
b) Beta-chain-binding superantigens.....	12
c) Alpha- and Beta-chain-binding superantigens.....	14
d) Superantigen affinity for MHC class II.....	16
e) Biological consequences of MHC class II binding.....	18
1.1.6 Superantigen interaction with TCR.....	18
a) Conformation-dependent superantigens.....	22
b) Conformation- and sequence-dependent superantigens.....	23
c) Sequence-dependent superantigens.....	23
d) Affinity and biological consequences of the superantigen-TCR interaction.....	25
1.1.7 TCR-superantigen-MHC complex.....	26
1.1.8 Influence of other receptors on superantigen-mediated immune responses.....	29
1.1.9 Superantigens and disease.....	31
a) Toxic shock syndrome.....	31



b)	Staphylococcal food poisoning.....	31
c)	Kawasaki syndrome.....	32
d)	Autoimmune diseases.....	32
1.1.10	Therapeutic strategies for superantigen-mediated disease.....	33
1.2	Antigen processing and presentation.....	34
1.2.1	Overview.....	34
1.2.2	Classical MHC class I antigen processing and presentation.....	34
a)	Peptide generation.....	36
b)	TAP and peptide translocation.....	37
c)	Assembly of MHC class I complexes.....	38
1.2.3	Classical MHC class II antigen processing and presentation.....	39
a)	Peptide generation.....	39
b)	MHC class II assembly and trafficking.....	39
c)	Formation of peptide-MHC class II complexes.....	40
1.2.4	Pathogen evasion strategies.....	42
a)	Evasion of MHC class I presentation.....	42
b)	Evasion of MHC class II presentation.....	43
1.2.5	Alternate MHC class I presentation pathways.....	44
a)	Phagosome-to-cytosol pathway.....	46
b)	Vacuolar pathway.....	47
1.2.6	Alternate MHC class II presentation pathways.....	47
1.3	Vaccines.....	49
1.3.1	Overview.....	49
1.3.2	Live, attenuated, inactivated and killed vaccines.....	50
1.3.3	Subunit vaccines.....	51
1.3.4	Conjugate vaccines.....	52
1.3.5	DNA vaccines.....	53
1.3.6	Adjuvants.....	54
1.3.7	New approaches for generating CTL responses.....	55
a)	Liposomes and microspheres.....	55
b)	Virus-like particles.....	56
c)	Heat-shock proteins.....	57
d)	Toxin-mediated vaccines.....	57



1.4 Aims .....	60
----------------	----

CHAPTER 2  
Materials and Methods

MATERIALS

2.1 Molecular biology reagents.....	61
2.1.1 Common buffers .....	61
2.1.2 DNA .....	61
(a) Reagents .....	61
(b) Plasmids.....	62
(c) Synthetic oligonucleotides.....	63
2.1.3 Proteins .....	64
(a) Reagents .....	64
(b) Antibodies.....	65
(c) Superantigen mutant genes.....	65
(d) Peptides.....	66
2.2 Bacterial culture reagents.....	67
2.2.1 Media .....	67
2.2.2 Selective antibiotics .....	67
2.2.3 Bacterial strains.....	68
2.2.4 Buffers for preparation of competent cells .....	68
2.3 Eukaryotic cell culture reagents.....	69
2.3.1 Buffers.....	69
2.3.2 Media .....	69
2.3.3 Additional culture reagents .....	70
2.3.4 Cell lines .....	71
2.4 Mouse strains .....	72

METHODS

2.5 Methods for DNA work .....	73
2.5.1 DNA extraction from bacteria (Plasmid prep).....	73
2.5.2 DNA purification .....	73

(a)	Ethanol precipitation of DNA.....	73
(b)	Isopropanol precipitation of DNA.....	73
(c)	Removing RNA from DNA preparations.....	74
(d)	Phenol/chloroform purification.....	74
(e)	Alkaline/ethidium purification.....	74
(f)	DNA purification from agarose gels.....	74
(g)	Direct purification of DNA from PCR amplifications.....	74
2.5.3	DNA analysis and manipulation.....	75
(a)	Agarose gel electrophoresis.....	75
(b)	Restriction enzyme digests.....	75
(c)	Ligations.....	75
(d)	Polymerase chain reaction (PCR).....	75
(e)	T-tailing pBlueScript for cloning PCR fragments.....	76
(f)	Site-directed mutagenesis by overlap PCR.....	76
(g)	Single colony PCR.....	76
2.5.4	Transformation.....	77
(a)	Preparation of chemically competent cells.....	77
(b)	Transformation of chemically competent cells.....	77
2.6	Methods for protein work.....	78
2.6.1	Protein expression from recombinant bacteria.....	78
2.6.2	Protein purification.....	78
(a)	Preparation of glutathione or iminodiacetic acid sepharose.....	78
(b)	GSH affinity chromatography.....	79
(c)	CM cation exchange chromatography.....	79
(d)	HS HPLC cation exchange chromatography.....	79
(e)	Ni <sup>2+</sup> affinity chromatography.....	80
(f)	Polymyxin B.....	80
2.6.3	Protein manipulations and analysis.....	80
(a)	Sodium dodecyl sulphate polyacrylamide gel electrophoresis.....	80
(b)	Electrophoresis of proteins under reducing and non-reducing conditions.....	81
(c)	Coomassie Blue staining of SDS-PAGE gels.....	81
(d)	Iodination of proteins.....	81
(e)	Fluorescent labelling of proteins.....	81

2.7 Cell culture methods .....	82
2.7.1 Production of GM-CSF .....	82
2.7.2 Generation of murine dendritic cells.....	82
2.7.3 Activation of THP-1 cells .....	82
2.8 Experimental procedures.....	83
2.8.1 Conjugation of peptides to proteins .....	83
(a) Conjugation by oxidation .....	83
(b) Conjugation via chemical cross-linkers.....	83
2.8.2 Superantigen interaction studies .....	84
(a) Analysis of leukocyte binding .....	84
(b) Analysis of binding to LG-2 or THP-1 cells .....	84
(c) Neutralisation of superantigen binding to LG-2 cells .....	84
(d) Cellular localisation of superantigens using fluorescence microscopy .....	85
(e) Cellular localisation of superantigens using confocal microscopy .	85
2.8.3 Functional effects of superantigens on dendritic cells .....	85
2.8.4 <i>In vivo</i> trafficking of superantigens .....	86
2.8.5 <i>In vitro</i> proliferation assays.....	86
(a) Mouse .....	86
(b) Human .....	86
2.8.6 <i>In vitro</i> CTL assay.....	87
2.8.7 <i>In vivo</i> CTL assay .....	88
(a) Preparation of target cells .....	88
2.8.8 Depletion of CD25+ T cells.....	88
2.8.9 Tumour challenge model .....	89
2.8.10 Viral challenge model .....	89
(a) Plaque assay.....	89

## CHAPTER 3

### Identification and analysis of TCR and MHC class II-binding residues of SPEC, SMEZ-2 and SEA

3.1 Introduction .....	91
3.2 Results .....	93
3.2.1 Cloning and expression of superantigen mutants .....	93
a) Purification of recombinant superantigens using the pGEX system	96
b) Purification of recombinant superantigens using the pET system ..	97
3.2.2 Mitogenicity of superantigens and their mutants on human PBMCs .....	99
3.2.3 Activity of superantigens and their mutants on murine lymphocytes.....	104
3.3 Summary .....	108

## CHAPTER 4

### Investigation of the mechanism-of-action of superantigen-mediated vaccine delivery

4.1 Introduction .....	109
4.2 Results .....	110
4.2.1 Superantigen binding to human cells <i>in vitro</i> .....	110
a) Human whole blood interactions.....	110
b) LG-2 cell interactions .....	112
c) THP-1 cell interactions.....	117
4.2.2 Superantigen binding to murine cells <i>in vitro</i> .....	119
4.2.3 Superantigen-mediated regulation of costimulatory molecule expression	122
4.2.4 <i>In vivo</i> trafficking studies.....	123
4.3 Summary .....	126

## CHAPTER 5

### Investigation of superantigen vaccine delivery using the LCMV system

5.1 Introduction .....	128
5.2 Results .....	129

5.2.1	Conjugation of GP33 to proteins .....	129
	a) Direct conjugation by oxidation reaction .....	129
	b) Conjugation using chemical cross-linkers.....	130
5.2.2	<i>In vitro</i> proliferation assays using cells from 318 tg mice.....	131
5.2.3	<i>In vitro</i> CTL assays.....	136
5.2.4	<i>In vivo</i> CTL assays.....	140
5.2.5	<i>In vivo</i> tumour protection studies.....	146
	a) Protection against LL-LCMV tumour cells.....	147
	b) Protection against B16.gp33 tumour cells.....	150
	c) Addressing MHV infection issues.....	152
5.2.6	<i>In vivo</i> viral protection studies.....	154
5.3	Summary .....	156

## CHAPTER 6

### Discussion

6.1	Overview .....	157
6.2	Donor, species and strain-specific differences in T cell mitogenicity of superantigens.....	159
6.3	Effects of TCR-binding-deficient superantigens on antigen presenting cells.....	162
6.4	Neutralisation of superantigen binding .....	166
6.5	Do TCR-binding-deficient superantigens induce T cell tolerance? .....	168
6.6	Antigenicity and immunogenicity of superantigen conjugates in mouse models...	169
6.7	Conclusions .....	174
6.8	Future directions.....	175
	Bibliography.....	177



## List of figures

<b>Figure 1.1</b>	The superantigen family of <i>S. aureus</i> and <i>S. pyogenes</i> .....	2
<b>Figure 1.2</b>	Crystal structures of two streptococcal superantigens and two staphylococcal superantigens.....	5
<b>Figure 1.3</b>	Secondary sequence alignment of the eleven crystallised superantigens .	6
<b>Figure 1.4</b>	Ribbon diagram of the N-terminal domain of SEA .....	7
<b>Figure 1.5</b>	Ribbon diagram of the C-terminal domain of SEA and SMEZ-2.....	8
<b>Figure 1.6</b>	Open-rendered ribbon diagram of three structurally aligned superantigens showing the C-terminal $\beta$ -sheet zinc-binding residues .....	9
<b>Figure 1.7</b>	A Schematic diagram of MHC molecules .....	10
<b>Figure 1.8</b>	Co-crystal structures of TSST-1 and SEB bound to HLA-DR .....	12
<b>Figure 1.9</b>	Co-crystal structure of SPEC bound to HLA-DR2 .....	13
<b>Figure 1.10</b>	Co-crystal structure of SEA D227A bound to HLA-DR1 .....	15
<b>Figure 1.11</b>	A schematic diagram of the different MHC class II-binding modes of superantigens.....	16
<b>Figure 1.12</b>	Schematic representation of the T cell receptor.....	19
<b>Figure 1.13</b>	Co-crystal structures of superantigens complexed with TCR V $\beta$ .....	24
<b>Figure 1.14</b>	Molecular surface structure of the TCR-binding site on four superantigens.....	25
<b>Figure 1.15</b>	Backbone representation of a TCR-pMHC complex.....	27
<b>Figure 1.16</b>	Comparison of the TCR-pMHC complex with models of TCR-superantigen-pMHC complexes .....	28
<b>Figure 1.17</b>	Schematic representation of the immunological synapse .....	29
<b>Figure 1.18</b>	Overview of the classical MHC class I processing pathway .....	35
<b>Figure 1.19</b>	Schematic diagram of a proteasome .....	37
<b>Figure 1.20</b>	Assembly of peptide-MHC class I complexes.....	38
<b>Figure 1.21</b>	Overview of the MHC class II processing and presentation pathways.....	41
<b>Figure 1.22</b>	The two major pathways of cross-presentation.....	45
<b>Figure 1.23</b>	Model of ER-membrane donation.....	48
<b>Figure 3.1</b>	SDS-PAGE analysis of SMEZ-2 M1 expression using the pGEX system .....	96
<b>Figure 3.2</b>	Purification of superantigens expressed using the pGEX system.....	97

<b>Figure 3.3</b>	Expression and purification of SEA Y64A using the pET system .....	98
<b>Figure 3.4</b>	<i>In vitro</i> stimulation of human PBMCs with SEA .....	100
<b>Figure 3.5</b>	<i>In vitro</i> stimulation of human PBMCs with SPEC .....	102
<b>Figure 3.6</b>	<i>In vitro</i> stimulation of human PBMCs with SMEZ-2.....	103
<b>Figure 3.7</b>	<i>In vitro</i> stimulation of murine cells with SEA WT and SEA QuinC.....	105
<b>Figure 3.8</b>	<i>In vitro</i> stimulation of murine cells with SPEC .....	106
<b>Figure 3.9</b>	<i>In vitro</i> stimulation of murine cells with SMEZ-2.....	107
<b>Figure 4.1</b>	Binding of SMEZ-2 M1 to whole human blood as analysed by flow cytometry .....	111
<b>Figure 4.2</b>	MHC class II expression and superantigen binding on LG-2 cells.....	112
<b>Figure 4.3</b>	Flow cytometry analysis of superantigens binding to LG-2 cells.....	113
<b>Figure 4.4</b>	SMEZ-2 M1 binding of LG-2 cells imaged on a Nikon E600 fluorescence microscope.....	114
<b>Figure 4.5</b>	Neutralisation of SMEZ-2 M1 binding to LG-2 cells.....	116
<b>Figure 4.6</b>	Flow cytometry analysis of MHC class II expression and superantigen binding on THP-1 cells .....	118
<b>Figure 4.7</b>	SMEZ-2 M1 binding of IFN- $\gamma$ -activated THP-1 cells imaged on a Nikon E600 fluorescence microscope.....	119
<b>Figure 4.8</b>	MHC class II expression and superantigen binding to murine blood cells .....	120
<b>Figure 4.9</b>	Superantigen binding and internalisation by mBMDCs .....	121
<b>Figure 4.10</b>	Costimulatory molecule expression on C57BL/6 splenic DCs in response to <i>in vivo</i> administration of bacterial antigens .....	122
<b>Figure 4.11</b>	<i>In vivo</i> trafficking of superantigens after subcutaneous, intravenous and intraperitoneal injection.....	124
<b>Figure 4.12</b>	<i>In vivo</i> trafficking of SMEZ-2 mutants after subcutaneous and intravenous injection.....	125
<b>Figure 5.1</b>	Conjugation of GP33 to SMEZ-2 M1 by oxidation.....	130
<b>Figure 5.2</b>	Conjugation of GP33 to SMEZ-2 M0 or ovalbumin using the chemical cross-linker SMBS.....	131
<b>Figure 5.3</b>	Antigenicity of the original and modified version of GP33.....	132
<b>Figure 5.4</b>	Antigenicity of SEA QuinC-GP33 conjugates <i>in vitro</i> .....	133
<b>Figure 5.5</b>	Antigenicity of SPEC-GP33 conjugates <i>in vitro</i> .....	134
<b>Figure 5.6</b>	Antigenicity of SMEZ-2-GP33 conjugates <i>in vitro</i> .....	135



<b>Figure 5.7</b>	SMEZ-2 M1 coupled to GP33 elicits specific CTL responses <i>in vitro</i> ...	137
<b>Figure 5.8</b>	<i>In vitro</i> CTL assay showing the effect of a non-superantigenic carrier protein and method of conjugation on carrier-enhanced antigenicity.....	138
<b>Figure 5.9</b>	MHC class II binding was not essential for superantigen-mediated enhancement of GP33-specific antigenicity <i>in vitro</i> .....	139
<b>Figure 5.10</b>	<i>In vivo</i> CTL assay showing difference in lysis of GP33-specific targets .	141
<b>Figure 5.11</b>	IFA was required to generate CTL responses <i>in vivo</i> .....	142
<b>Figure 5.12</b>	<i>In vivo</i> CTL assay showing dose titration of GP33 alone, SMEZ-2 M1-GP33, and SMEZ-2 M1 + GP33 .....	143
<b>Figure 5.13</b>	MHC class II binding was important for enhanced immunogenicity of superantigen-GP33 conjugates <i>in vivo</i> .....	144
<b>Figure 5.14</b>	Regulatory T cells did not negatively affect the immunogenicity of SMEZ-2 M1-GP33 <i>in vivo</i> .....	145
<b>Figure 5.15</b>	Enhanced memory response with SMEZ-2 M1-GP33 conjugates <i>in vivo</i>	146
<b>Figure 5.16</b>	LL-LCMV tumour protection assay 1 .....	148
<b>Figure 5.17</b>	LL-LCMV tumour protection assay 2 .....	149
<b>Figure 5.18</b>	B16.gp33 tumour protection assay.....	151
<b>Figure 5.19</b>	The effect of MHV infection on <i>in vitro</i> immune responses .....	153
<b>Figure 5.20</b>	SMEZ-2 M1-GP33 protects against viral challenge in a dose-dependent manner.....	155

## List of Tables

<b>Table 1.1</b>	MHC class II-binding modes of several superantigens .....	11
<b>Table 1.2</b>	TCR V $\beta$ specificities of staphylococcal and streptococcal superantigens	21
<b>Table 1.3</b>	Comparison of different vaccine approaches .....	50
<b>Table 2.1</b>	Primers used for site directed mutagenesis of the SEA gene.....	63
<b>Table 3.1</b>	Expression and yield of SEA and its mutants .....	94
<b>Table 3.2</b>	Description, expression and yield of SPEC and its mutants .....	95
<b>Table 3.3</b>	Description, expression and yield of SMEZ-2 and its mutants.....	95
<b>Table 3.4</b>	P <sub>50</sub> and reduction in P <sub>max</sub> values of single point mutations of SEA .....	101
<b>Table 3.5</b>	P <sub>50</sub> and P <sub>max</sub> values of combined point mutations of SEA .....	101
<b>Table 6.1</b>	Comparison of superantigen potency on human PBMCs .....	159
<b>Table 6.2</b>	Comparison of superantigen potency on murine and human lymphocytes .....	161

## Abbreviations

°C	Degrees Celsius
2-ME	2-mercaptoethanol
APC	Antigen presenting cell
APS	Ammonium persulfate
ATP	Adenosine triphosphate
$\beta_2m$	$\beta_2$ -microglobulin
BiP	Immunoglobulin heavy chain binding protein
BMDC	Bone marrow-derived dendritic cell
CD	Cluster of differentiation
CDR	Complementary determining region
CFA	Complete Freund's adjuvant
CFSE	Carboxyfluorescein diacetate succinimidyl ester
CLIP	Class II-associated invariant chain peptide
CPM	Counts per minute
C-terminal	Carboxy-terminal
CTL	Cytotoxic T lymphocyte
CTLA	Cytotoxic T lymphocyte-associated antigen
CV	Column volumes
CyaA	Adenylate cyclase toxin
C $\alpha$	Constant region of the T cell receptor $\alpha$ -chain
C $\beta$	Constant region of the T cell receptor $\beta$ -chain
DAPI	4',6-diamidino-2-phenylindole
DC	Dendritic cell
ddH <sub>2</sub> O	Deionised water
DMA	N,N-dimethylacetamide
DMEM	Dulbecco's modified eagle medium
DNA	Deoxyribonucleic acid
dNTP	Deoxynucleotide triphosphate
DTT	Dithiothreitol
dTTP	Deoxythymidine triphosphate
E:T	Effector:target
EBV	Epstein-Barr virus
EDTA	Ethylenediaminetetraacetic acid
EF	edema factor
EMEM	Eagle's minimum essential medium
ER	Endoplasmic reticulum
Fab	Antigen binding fragment
FACS	Fluorescent activated cell sorter
FCS	Foetal calf serum
FITC	Fluorescein isothiocyanate
FR	Framework region
g	Gram or gravity
GM-CSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GSH	Glutathione
GST	Glutathione-S-transferase
h	Hour or hours
HA	Hem agglutinin

HBsAg	Hepatitis B surface antigen
HCMV	Human cytomegalovirus
Hib	<i>Haemophilus influenzae</i> type B
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HPLC	High performance liquid chromatography
HPV	Human papilloma virus
HSP	Heat-shock protein
HSV	Herpes simplex virus
HV	Hypervariable region
ICAM	Intracellular adhesion molecule
IDA	Iminodiacetic Acid
IFA	Incomplete Freund's adjuvant
IFN	Interferon
Ii	Invariant chain
IL	Interleukin
IPTG	Isopropylthiogalactose
IVIG	Intravenous immunoglobulin
kDa	Kilo Daltons
KSHV	Kaposi's sarcoma-associated herpes virus
L	Litre
LB	Luria-Bertani broth
LCMV	Lymphocytic choriomeningitis virus
LF	Lethal factor
LFA	Leukocyte function-associated antigen
LMP	Low molecular weight protein
LPS	Lipopolysaccharide
M	Molar
mA	Milliamperes
mBMDC	Murine bone marrow-derived dendritic cell
MCS	Multiple cloning site
MECL	Multicatalytic endopeptidase complex like
mg	Milligram
MHC	Major histocompatibility complex
MHV	Mouse hepatitis virus
MIIC	MHC class II compartment
μl	Microlitre
μM	Micromolar
min	Minutes
ml	Millilitre
mM	Millimolar
MOPS	3-(N-Morpholino) propanesulfonic acid
MQ H <sub>2</sub> O	MilliQ water
MW	Molecular weight
ng	Nanogram
NHS	N-hydroxysuccinimide
N-terminal	Amino-terminal
OMP	Outer membrane protein
PA	Protective antigen
PAMP	Pathogen associated molecular patterns
PBMC	Peripheral blood mononuclear cell

pBS	pBlueScript
PBS	Phosphate-buffered saline
PCR	Polymerase chain reaction
pfu	Plaque-forming units
pg	Picogram
pMHC	peptide-MHC complex
PMSF	Phenyl methyl sulphonyl fluoride
RBC	Red blood cell
RNA	Ribonucleic acid
rpm	Revolutions per minute
RPMI	Roswell Park Memorial Institute medium
RT	Room temperature
SCID	Severe combined immune deficiency
SD	Standard deviation
SDS	Sodium dodecyl sulphate
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SE	Staphylococcal enterotoxin
SMBS	Sulfo- <i>m</i> -maleimidobenzoyl- <i>N</i> -hydroxysuccinimide ester
SPE	Streptococcal pyrogenic exotoxin
Spp.	Denotes more than one species
SSA	Streptococcal superantigen
TAP	Transporter associated with antigen processing
TB	Terrific broth
TCR	T cell receptor
TEMED	N,N,N',N'-Tetramethylethylenediamine
TFB	Transformation buffer
tg	Transgenic
TGN	Transgolgi network
Th	T helper cell
TLR	Toll-like receptor
TNF	Tumour necrosis factor
TP	Tryptone-phosphate medium
TPCK	L-1-tosylamido-2-phenylethyl chloromethyl ketone
Tris	2-amino-2-(hydroxymethyl)propane-1,3-diol
TSS	Toxic shock syndrome
TSST	Toxic shock syndrome toxin
VCAM	Vascular cell adhesion molecule
VLP	Virus-like particles
V $\alpha$	Variable region of the T cell receptor $\alpha$ -chain
V $\beta$	Variable region of the T cell receptor $\beta$ -chain
WT	Wild-type